Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving nucleic acid
Reexamination Certificate
2006-06-12
2011-11-01
Bausch, Sarae (Department: 1634)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving nucleic acid
C435S091100, C436S063000
Reexamination Certificate
active
08048622
ABSTRACT:
The present invention provides diagnostic markers of neuropsychiatric disorders (e.g., schizophrenia, schizoaffective disorder or serious mood disorders including bipolar disorder and recurrent unipolar disorder) for use in diagnosis, drug screening, therapy monitoring, research and therapeutic applications. In particular, the present invention provides SLC18A1 and TAAR2, and mutations therein, as biomarkers of neuropsychiatric disorders.
REFERENCES:
patent: 7736852 (2010-06-01), Berrettini et al.
Lohoff et al. (Neuropsychopharmacology, vol. 31, pp. 2739-2747, 2006).
Richards et al. (Behavioral and Brain Functions, 2006, vol. 2, No. 39, pp. 1-6).
Chen et al. (Schizophrenia Research, 2007, vol. 90, pp. 363-365, 2007).
Ionnidis (Plost Med, 2005, 2(8):e124).
Newton-Cheh (Mutation Research 2005, 573, pp. 54-69).
Iwasa et al. (J Human Genet (2001) vol. 46:549-552).
Tate et al. (Nature Genetics Supplement, Nov. 2004, vol. 11, pp. S43-S42).
Blouin, et al., “Schizophrenia susceptibility loci on chromosomes 13q32 and 8p21”, Nature Genetics (1998) pp. 70-73, vol. 20.
Brzustowicz, et al., “Linkage of Familial Schizophrenia to Chromosome 13q32”, Am. J. Hum. Gen. (1999) pp. 1096-1103, vol. 65.
Erickson, et al., “Distinct pharmacological properties and distribution in neurons and endocrine cells of two isoforms of the human vesicular monoamine transporter”, Proc. Natl. Acad. Sci. U. S. A. (1996) pp. 5166-5171, vol. 93.
Gurling, et al., “Genomewide Genetic Linkage Analysis Confirms the Presence of Susceptibility Loci for Schizophrenia, on Chromosomes 1q32.2, 5q33.2, and 8p21-22 and Provides Support for Linkage to Schizophrenia, on Chromosomes 11q23.3-24 and 20q12.1-11.23”, Am. J. Hum. Genet. (2001) pp. 661-673, vol. 68.
Bly, “Mutation in the vesicular monoamine gene, SLC18A1, associated with schizophrenia”, Schizophrenia Research (2005) pp. 337-338, vol. 78.
Hayashi, et al., “Vesicular Monoamine Transporter 1 Is Responsible for Storage of 5-Hydroxytryptamine in Rat Pinealocytes”, J. Neurochem. (1999) pp. 2538-2545, vol. 73.
Woolley and Shaw, “A Biochemical and Pharmacological Suggestion About Certain Mental Disorders”, PNAS (1954) pp. 228-231, vol. 40.
Schwab, et al.,“A genome-wide autosomal screen for schizophrenia susceptibility loci in 71 families with affected siblings: support for loci on chromosome 10p and 6.”, Molecular Psychiatry, (2000) pp. 638-649, vol. 5.
Levinson, et al., “Multicenter Linkage Study of Schizophrenia Candidate Regions on Chromosomes 5q, 6q, 10p, and 13q: Schizophrenia Linkage Collaborative Group III”, Am. J. Hum. Genet. (2000) pp. 652-663, vol. 67.
Bausch Sarae
Casimir Jones S.C.
The Regents of the University of Michigan
LandOfFree
Identifying increased susceptibility to schizophrenia does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Identifying increased susceptibility to schizophrenia, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Identifying increased susceptibility to schizophrenia will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4311344